Clinical Trials in Finland

• Dual antiplatelet therapy with ticagrelor and acetylsalicylic acid (ASA) vs. ASA only after isolated coronary artery bypass grafting in pati… Ended
  2023-508551-40-00 Phase IV Coronary artery multi-vessel disease and left main stenosis Vaestra Goetalandsregionen
• A Study of Relatlimab plus Nivolumab Versus Nivolumab Alone in Participants with Advanced Melanoma Ended
  2024-510913-13-00 Phase II/III Previously Untreated Metastatic or Unresectable Melanoma Bristol-Myers Squibb Services Unlimited Company
• A Phase 1/2, Open-Label, Dose-Escalation Trial of GEN3013 in Patients with Relapsed, Progressive or Refractory B-Cell Lymphoma Ended
  2023-504802-12-00 Phase I (FiH) Lymphoma of B-cell origin Genmab A/S
• International Study for Treatment of High Risk Childhood Relapsed ALL 2010 - A randomized Phase II Study Conducted by the Resistant Disease … Ended
  2024-513070-21-00 Phase II Relapsed Acute Lymphoblastic Leukemia (ALL) Charite Universitaetsmedizin Berlin KöR
• ENRICH - Randomised, open label study of Rituximab/Ibrutinib vs Rituximab/Chemotherapy in older patients with untreated mantle cell lymphoma Ended
  2024-514275-18-00 Phase II/III Mantle Cell Lymphoma (MCL) Region Skane; University Hospitals Plymouth NHS Trust
• International trial in Philadelphia chromosome-positive acute lymphoblastic leukemia Ended
  2024-515499-12-00 Phase III Acute lymphoblastic leukemia Universita Degli Studi Di Milano Bicocca
• Treatment of peritoneal dissemination in stomach cancer patients with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy; P… Ended
  2023-510159-53-01 Phase II peritoneal dissemination in stomach cancer patients Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
• DupuytrEn Treatment EffeCtiveness Trial (DETECT) Ended
  2024-515110-40-00 Phase III Dupuytren's contracture Pirkanmaan hyvinvointialue
• B-NHL 2013 - Treatment protocol of the NHL-BFM and the NOPHO study groups for mature aggressive B-cell lymphoma and leukemia in children and… Ended
  2023-505509-18-00 Phase III mature aggressive B-cell lymphoma and leukemia in children a… Universitaetsklinikum Muenster AöR
• Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer (monarchE) Ended
  2023-509671-17-00 Phase III Breast Cancer Eli Lilly & Co.
• Long Term Safety and Efficacy of ABT-494 in Subjects with Ulcerative Colitis. Ended
  2023-505699-31-00 Phase III Ulcerative Colitis AbbVie Deutschland GmbH & Co. KG
• A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study Ended
  2023-510298-33-00 Phase II Prostate Cancer Astellas Pharma Global Development Inc.
• A prospective phase II study to assess the minimal residual disease after ixazomib plus lenalidomide plus dexamethasone (IRd) treatment for … Ended
  2024-517321-99-00 Phase II Myeloma multiplex HUS-Yhtymae
• A Study with an active treatment to Assess the Long-term Safety of Weekly Intravenous Product in Subjects with Pulmonary Emphysema due to Al… Ended
  2024-513962-20-00 Phase III Pulmonary Emphysema due to Alpha-1-Antitrypsin Deficiency Grifols Therapeutics LLC
• An international study to evaluate the safety and effectiveness of enzalutamide plus leuprolide, enzalutamide alone, and leuprolide alone in… Ended
  2024-513521-23-00 Phase III Prostate Cancer Medivation Inc.
• Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab (MK-3475) versus placebo after complete resection of high-risk Stage… Ended
  2023-509136-25-00 Phase III Stage III melanoma (AJCC R0) with histologically confirmed c… Merck Sharp & Dohme LLC
• Further 2 years of adjuvant imatinib may improve recurrence-free survival (RFS) of patients who are at a high risk of GIST recurrence despit… Ended
  2024-512243-23-00 Phase III gastrointestinal stromal tumor Region Skane
• A Controlled Study with an active treatment and a Placebo to Assess the Efficacy and Safety of Weekly Intravenous Product in Subjects with P… Ended
  2023-510030-83-00 Phase III Pulmonary Emphysema due to Alpha-1-Antitrypsin Deficiency Grifols Therapeutics LLC
• Study of efficacy and safety of JDQ443 in comparison with docetaxel in participants with locally advanced or metastatic KRAS G12C mutant non… Halted
  2023-510082-10-00 Phase III Advanced non-small cell lung cancer harboring the KRAS G12C … Novartis Pharma AG
• GSK4527226 Open-label Extension Study in Patients with Early Alzheimer's Disease. Ended
  2025-521107-42-00 Phase II Alzheimer's Disease Glaxosmithkline Research & Development Limited
• Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, immunogenicity and safety of one dose of… Ended
  2024-520354-37-00 Phase II Influenza disease Osivax
• A Phase 3 study to assess the immune response and safety of rMenB+OMV NZ in primed healthy participants (10 to 20 years old) Ended
  2024-519549-31-00 Phase III Invasive meningococcal disease (IMD) GlaxoSmithKline Biologicals
• Accelerator-based BNCT for head and neck carcinoma Ended
  2024-515036-71-00 Phase I (Other) Head and neck carcinoma HUS-Yhtymae; Neutron Therapeutics Finland Oy
• A study to evaluate S227928 as a Single Agent and in Combination with Venetoclax in Patients with R/R AML, MDS/AML, or CMML Ended
  2024-514356-33-00 Phase I (FiH) "Patients with Relapsed/Refractory (R/R) Acute Myeloid Leuke… Institut De Recherches Internationales Servier IRIS

Showing 409–432 of 533 trials